Interestingly, CD37 antibody-based therapeutics currently in (pre-)clinical development are poor inducers of complement-dependent cytotoxicity (CDC)5–7, another powerful Fc-mediated effector mechanism for killing hematological cancer cells22,23. The gene discussed is CD37; the disease is hematopoietic and lymphoid cell neoplasm.